TrialThe American journal of cardiology2018

Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein.

Cory R Trankle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.